Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

被引：4
|
作者：
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134383
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
    Einsele, H.
    Kansagra, A.
    Lin, Y.
    Berdeja, J.
    Shah, N.
    Oriol, A.
    Yakoub-Agha, I
    Rambaldi, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Wang, J.
    Agarwal, A.
    Campbell, T. B.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
  • [2] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
    Raje, Noopur S.
    Siegel, David S.
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil C.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy B.
    San-Miguel, Jesus F.
    Reece, Donna E.
    BLOOD, 2020, 136
  • [3] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
    Albert, Oriol
    Ankit, Kansagra
    Yi, Lin
    Jesus, Berdeja
    Nina, Shah
    Ibrahim, Yakoub-Agha
    Hermann, Einsele
    Alessandro, Rambaldi
    Anna, Truppel-Hartmann
    Everton, Rowe
    Julie, Wang
    Amit, Agarwal
    Timothy, Campbell B.
    Sagar, Lonial
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
  • [4] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [5] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
    Goldschmidt, Hartmut
    Raje, Noopur
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil
    Moreau, Philippe
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy
    San-Miguel, Jesus
    Reece, Donna
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
  • [6] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
    Weisel, K.
    Manier, S.
    Kansagra, A.
    Anderson, Jr L. D.
    Berdeja, J.
    Jagannath, S.
    Lin, Y.
    Lonial, S.
    Shah, N.
    Raje, N.
    Siegel, D.
    Oriol, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Patel, P.
    Agarwal, A.
    Campbell, T. B.
    Rodriguez-Otero, P.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
  • [7] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [8] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [9] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
    Einsele, Hermann
    Berdeja, Jesus
    Raje, Noopur
    Siegel, David
    Lin, Yi
    Anderson, Larry, Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy
    Jagannath, Sundar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
  • [10] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study
    Goldschmidt, H.
    Raje, N. S.
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Munshi, N. C.
    Moreau, P.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Huang, L.
    Agarwal, A.
    Wang, J.
    Campbell, T. B.
    San-Miguel, J.
    Reece, D. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 18 - 19
12345